Pharmacokinetics and Pharmacodynamics of MK-5046, a Bombesin Receptor Subtype-3 (BRS-3) Agonist, in Healthy Patients.
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2012
At a glance
- Drugs MK 5046 (Primary)
- Indications Obesity
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 09 Jan 2012 New trial record
- 12 Dec 2011 Results published in the Journal of Clinical Pharmacology.